COVID-19 to become seasonal? Herd immunity will decide frequency of outbreak, claims studyScientists have predicted that coronavirus will become a seasonal virus in countries with temperate climates only when herd humanity is attained. Until then, public health measures must be followed to curb the spread of the virus, a review published in Frontiers highlighted. Dr Hassan Zaraket of the American University of Beirut in Lebanon, added, \"COVID-19 is here to stay and it will continue to cause...

In August, Novavax signed a deal with Serum Institute, the world's largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low- and middle-income countries and India

COVID-19 vaccine candidates being developed by Cadila Healthcare and Bharat Biotech have completed the phase one of the study while Pune-based Serum Institute of India (SII) will begin with Phase 3 clinical trial after getting regulatory nod, says ICMR chief

Where the UK has resumed the clinical tests of AstraZeneca's COVID-19 vaccine candidate following a review by the country's drug regulator and an independent safety review committee, trials paused in India, US, and South Africa are yet to resume

In India, the Bill and Melinda Gates Foundation has partnered with Serum Institute to ramp up the manufacturing and delivery of coronavirus vaccines

The head of the world's largest vaccine manufacturer said that the world will need 15 billion doses of the COVID-19 shot if it is a two-dose vaccine

Enrollment in AstraZeneca's global trials of the vaccine, which it is developing with researchers at Oxford University, was put on pause on September 6

Union Health Minister Harsh Vardhan on Sunday said that he will be the first person to take COVID-19 vaccine so as to dispel the \"trust deficit\" around the same

Pfizer says trial is event-based and there are many variables that will ultimately impact read-out timing; adds if trials are successful, these companies would submit vaccines for approval as early as October

\"Once DCGI (Drugs Controller General of India) gives us permission to restart the trials in India, we will resume the trials,\" SII CEO Adar Poonawalla said on Saturday

Bharat Biotech says its vaccine candidate was found to generate \"robust immune responses\", thus preventing infection and disease in primates upon high amounts of exposure to live SARS-CoV-2 virus

DCGI VG Somani in his order also asked Serum Institute to suspend any new recruitment in Phase 2 and 3 clinical trials until further notice; SII also need to increase safety monitoring of test subjects vaccinated under trials so far

Another leading candidate for coronavirus vaccine is Moderna. The company said that it is talking to multiple countries for the rollout of the COVID-19 vaccine.

Phase 2/3 COVID-19 vaccine trials being conducted across 17 sites in India paused till further instructions from regulator; could delay vaccine development process as Serum Institute is front-runner when it comes to companies producing COVID-19 vaccines in India

British-Swedish bio-pharmaceutical firm AstraZeneca PLC, working with a team of the University of Oxford, has temporarily paused the clinical trial of its coronavirus vaccine in the UK after one of the volunteers developed an 'unexplained' illness. Serum Institute CEO, Adar Poonawalla, referred to the issue as unrelated and said that it would not impact the vaccine trials in India. Watch the video for more.Also Read: AstraZeneca pauses COVID-19 trials: In which countries are the trials taking place?

AstraZeneca vaccine trials halted: Dr. Angela Rasmussen, virologist at Columbia University said that this is exactly why Phase 3 of clinical trials are so important. She added that this might not be a big deal

The initial symptoms of Transverse myelitis include pain in the lower back or sharp, shooting sensations that radiate down the arms, legs, or around the torso

Serum Institute CEO, Adar Poonawalla, told BusinessToday that the Indian trials, which were being conducted on the Oxford vaccine, had not been stopped yet. AstraZeneca PLC, which is working with a team of the University of Oxford, on Wednesday decided to temporarily pause the clinical trial of its coronavirus vaccine after one of the volunteers in the UK developed an 'unexplained' illness. Watch the video for more.Also Read: India coronavirus vaccine trials 'not stopped yet': Serum's Adar Poonawalla after AstraZeneca halts global trials

Serum has also started manufacturing the vaccine, targeting to use in India and 92 other countries upon completion of trials and regulatory clearances

The late-stage phase 3 clinical trial of AstraZeneca's COVID-19 vaccine is being conducted at various sites, including the United Kingdom, where the adverse event was reported